| CLIENTS |
CLIENTS |
92%
|
Cell Solutions which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow as well as cells from disease st… |
| ACADEMIC-INSTITUTIONS |
ACADEMIC-INSTITUTIONS |
90%
|
Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and c… |
| CONTRACT-RESEARCH-AND-CONTRACT-MANUFACTURING-ORG |
CONTRACT-RESEARCH-AND-CONTRACT-MANUFACTURING-ORG |
90%
|
Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and c… |
| GLOBAL-PHARMACEUTICAL-AND-BIOTECHNOLOGY-COMPANIE |
GLOBAL-PHARMACEUTICAL-AND-BIOTECHNOLOGY-COMPANIE |
90%
|
Our client base includes major global pharmaceutical companies, many biotechnology companies |
| GOVERNMENT-AGENCIES |
GOVERNMENT-AGENCIES |
90%
|
Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and c… |
| HOSPITALS |
HOSPITALS |
90%
|
Our client base includes major global pharmaceutical companies, many biotechnology companies; agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and c… |
| K-F-CAMBODIA-LTD |
K-F-CAMBODIA-LTD |
85%
|
safety testing services using next-generation sequencing and bioinformatics to support biopharmaceutical product development and manufacturing, resulting in a 100% controlling interest. The prelimina… |
| TWST |
Twist Bioscience Corporation |
72%
|
Reciprocal relationship from TWST graph: ies, Inc., Eurofins Genomics Blue Heron, Elegen Corporation, Ansa Biotechnologies, Inc., Telesis Bio, Inc. and others. Additionally, we compete with both larg… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
, or might not be fully enforceable. Our intellectual property rights might not prevent our competitors from independently developing intellectual property that is similar to or duplicative of ours. … |
| NOVEPRIM-GROUP |
NOVEPRIM-GROUP |
62%
|
ssures, we believe clients will continue to benefit from the long-term value of strategic outsourcing to improve their operating efficiency and to access capabilities that they do not maintain intern… |
| SAMDI-TECH-INC |
SAMDI-TECH-INC |
62%
|
hase the remaining 10% equity interest up until one month after the sixth anniversary of closing the 41% equity interest. On the first anniversary of the expiration of the call option, a 12-month put… |
